|1.||Walker, Bruce D: 3 articles (01/2015 - 11/2010)|
|2.||Saad, Jamil S: 3 articles (01/2015 - 11/2010)|
|3.||Freed, Eric O: 3 articles (11/2010 - 05/2008)|
|4.||Ndung'u, Thumbi: 2 articles (01/2015 - 11/2010)|
|5.||Ghanam, Ruba H: 2 articles (01/2012 - 11/2010)|
|6.||Rein, Alan: 2 articles (01/2011 - 11/2003)|
|7.||Shida, Hisatoshi: 2 articles (02/2009 - 02/2004)|
|8.||Gijsbers, Esther F: 1 article (08/2015)|
|9.||van Nuenen, Adrianus C: 1 article (08/2015)|
|10.||Setiawan, Laurentia C: 1 article (08/2015)|
|1.||HIV Infections (HIV Infection)
04/24/2010 - "The activity of virus-specific T lymphocytes, among which those capable of a polyfunctional response against the viral protein gag, is crucial to control HIV infection. "
11/01/2010 - "We studied the dominant HLA-Cw*03-restricted CTL response to YVDRFFKTL(296-304) (YL9), within the conserved major homology region (MHR) of the Gag protein, in 80 HLA-Cw*03-positive individuals with chronic HIV infection to better define the efficacy of the YL9 HLA-C-restricted response. "
01/01/2015 - "The findings suggest this immunodominant epitope in Gag protein, which is associated with VH4-59 germline gene usage, may induce a high level of B cells that encode binding but non-functional antibodies that occupy significant repertoire space following HIV infection. "
08/01/2006 - "Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. "
05/08/2012 - "To explore the human leukocyte antigen (HLA)-associated mutations in Gag protein of B' clade (human immunodeficiency virus-1) HIV-1 infected Han Chinese people and evaluate the impact of HLA associated Gag mutations on the disease progression of HIV infection. "
02/01/2014 - "We used enveloped virus-like particles (eVLPs), in which particles were produced in cells after the expression of murine leukemia virus (MLV) viral matrix protein Gag, to express either full-length CMV gB (gB eVLPs) or the full extracellular domain of CMV gB fused with the transmembrane and cytoplasmic domains from vesicular stomatitis virus (VSV)-G protein (gB-G eVLPs). "
03/01/2000 - "Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope."
10/10/2014 - "Significant improvement in adaptive immune responses in systemic and mucosal tissues was observed by including α-GalCer adjuvant for intranasal immunization of mice with vesicular stomatitis virus vector encoding the model antigen ovalbumin and adenoviral vectors expressing HIV env and Gag antigens. "
01/01/2013 - "In addition, studies have also shown that during the later stages of virus infection NS3 behaves similarly to HIV protein Gag, an enveloped viral protein. "
01/02/2015 - "These data underscore the importance of HIV-specific CD8 T-cell responses, particularly to the Gag protein, in the maintenance of low viral load levels during primary infection, and show that these responses are initially poorly elicited by natural infection. "
01/01/2015 - "Targeting of the Gag polyprotein to the plasma membrane (PM) for assembly is a critical event in the late phase of immunodeficiency virus type-1 (HIV-1) infection. "
01/01/2015 - "Using infection of DERSE and other human cell lines (HEK293T), no evidence for expression of glyco-gag by KoRV was found, either in expression of glyco-gag protein or changes in infectivity when the putative glyco-gag reading frame was mutated. "
05/01/2014 - "PDZD8 has been previously reported to bind the HIV-1 Gag polyprotein and to make a positive contribution to the efficiency of HIV-1 infection (M. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
10/21/2009 - "Human immunodeficiency virus type 1 (HIV-1) protease plays a fundamental role in the maturation and life cycle of the retrovirus HIV-1, as it functions in regulating post-translational processing of the viral polyproteins gag and gag-pol; thus, it is a key target of AIDS antiviral therapy. "
05/02/2008 - "The capsid domain of the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein is a critical determinant of virus assembly, and is therefore a potential target for developing drugs for AIDS therapy. "
07/07/2000 - "HIV-1 expression in the transgenic mouse spleen was activated 10- to 20-fold by LPS, and the serum p24 Gag protein levels reached 400 pg/ml, which is nearly equal to the levels that occur in AIDS patients. "
04/01/1988 - "Further analysis of the bovine IL-2R sequence also revealed the following: (i) the hydrophobic domains of the IL-2R protein were more conserved between species than the hydrophilic domains, (ii) the predominant site of intracellular IL-2R phosphorylation in mouse and human was a conserved Ser which was not conserved in the bovine sequence, and (iii) there exists a statistically significant amino acid homology with the AIDS gag protein."
01/01/1987 - "The quantitative analysis of sera with env and gag antigens by ELISA showed AIDS patients had very low gag reactivity while retaining high env reactivity. "
02/11/2009 - "Immunogenicity of newly constructed attenuated vaccinia strain LC16m8Delta that expresses SIV Gag protein."
04/15/1993 - "In vitro expanded CD8+ cells had excellent cytotoxic function at the time they were used for therapy, including HIV-specific activity against autologous targets infected with vaccinia vectors expressing HIV-IIIb antigens, gag, pol, and env. "
12/01/1992 - "The induced CTL also demonstrate antiviral immunity by recognizing SIV gag protein endogenously processed by target cells infected with SIV/vaccinia recombinant virus. "
11/01/1990 - "Immunization of mice and chimpanzees with vaccinia-HIVgag recombinant viruses generated both antibody and cell-mediated immune responses to HIV gag antigens. "
05/01/1992 - "Target cells included an HTLV-I-transformed cell line (C91/PL), an HTLV-II-transformed cell line (729pH6neo), and Epstein Barr virus (EBV)-transformed B lymphocytes expressing HTLV-I or -II env or gag gene products after infection with vaccinia/HTLV recombinants. "
|2.||HLA-C Antigens (HLA-C)
|5.||env Gene Products
|6.||DNA-Directed RNA Polymerases (RNA Polymerase)
|7.||Peptide Hydrolases (Proteases)
|8.||Proteins (Proteins, Gene)
|2.||Heterologous Transplantation (Xenotransplantation)